Figure 9.
Figure 9. FucTVI treatment does not affect the function of other homing receptors on cord blood CD34+ cells. Purified CB-CD34+ cells, FucTVI-treated or untreated, were assayed for (A) chemotaxis toward the chemokine CXCL12 and (B) adhesion to rhVCAM-1. Adhesion to VCAM-1 was specific since it was completely inhibited by an anti-α4 integrin antibody (HP2/1). No difference was observed in the activities of CXCR4 and α4 integrins between FucTVI-treated or untreated cord blood CD34+ cells. Shown are mean ± SEM values; n = 6 for panel A and n = 4 for panel B.

FucTVI treatment does not affect the function of other homing receptors on cord blood CD34+ cells. Purified CB-CD34+ cells, FucTVI-treated or untreated, were assayed for (A) chemotaxis toward the chemokine CXCL12 and (B) adhesion to rhVCAM-1. Adhesion to VCAM-1 was specific since it was completely inhibited by an anti-α4 integrin antibody (HP2/1). No difference was observed in the activities of CXCR4 and α4 integrins between FucTVI-treated or untreated cord blood CD34+ cells. Shown are mean ± SEM values; n = 6 for panel A and n = 4 for panel B.

Close Modal

or Create an Account

Close Modal
Close Modal